Big Pharma Enters Psychedelic Drug Market with Major Investments
A trend of major pharmaceutical companies investing in psychedelic drugs is emerging, with Eli Lilly making a significant deal worth up to $3.8 billion with AtaiBeckley, signaling a potential buyout spree in the sector.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (27/100)Sources
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Read full article →The Big Pharma Psychedelic Buyout Spree Has Begun
The Big Pharma Psychedelic Buyout Spree Has Begun Submitted by QTR's Fringe Finance Massive validation for psychedelics…not as drugs, but as investments could be moments away. Just months after I argued for the millionth time that psychedelic drug developers were likely to become acquisition targets as the sector gained legitimacy, it looks like the first major domino may finally be falling. According to a Bloomberg report published moments ago, Eli Lilly is in talks to acquire ...
By Tyler Durden
Read full article →
